Data on appropriate treatment for periampullary cancers are lacking. For the most part, clinicians tend to treat these cancers in the same way that they treat pancreatic cancers, with similar surgical ...
Dr. Liangyou concluded his presentation discussing the efficacy and safety of disitamab vedotin combined with tislelizumab as adjuvant therapy after radical surgery for patients with HER2-expression ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Meyerhardt is ...
MedPage Today on MSN
Pre-Op Chemo or Upfront Surgery in Colon Cancer: Is One Strategy Best?
"Optimal regimens and ideal patients remain undefined," experts say ...
EAU 2026: Preliminary Results of a Phase II Study to Evaluate the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Combination with Radiotherapy for Adjuvant Therapy in Upper Tract Urothelial ...
KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...
Please provide your email address to receive an email when new articles are posted on . Patients who started adjuvant chemotherapy more than 6 weeks after colorectal cancer surgery achieved poorer DFS ...
A shorter regimen of three cycles of adjuvant chemotherapy was noninferior to a standard six-cycle regimen among patients with pathologically high-risk retinoblastoma, a Chinese randomized trial ...
Preventive chemotherapy, or adjuvant chemotherapy, is administered after your primary cancer treatment. It’s used to destroy remaining cancer cells in your body that might be undetectable. Preventive ...
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: Extended follow-up of a randomized controlled trial and post-treatment immune cell profiling. Nivolumab (NIVO) plus ...
Please provide your email address to receive an email when new articles are posted on . A 14-gene molecular assay may help predict adjuvant chemotherapy benefit in early NSCLC. Patients assigned ...
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005 This international ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results